Prioritizing R&D Initiatives in Today’s Market
Dear Readers, As our economy continues to change, we thought it would be helpful to share some insights and industry patterns that we...
top of page
- Sep 12, 2022
Our Approach to Storytelling
Dear friends and colleagues, “Biotech’s flameout,” “bloodbath,” “thousands of layoffs.” We’ve all heard it, and we’re in it. Whether...
- Jul 29, 2022
5 Must-Have Slides for Investor Pitch Decks
To help our readers prepare for their next financing round, we’ve compiled a list of the 5 must-have slides for any investor pitch deck....
- Jul 29, 2022
Tips for Navigating a Conference
Dear Readers, As we gear up for conference season, we thought it could be helpful to share some tips on how to succeed while at a...
- Dec 8, 2021
Developments in Ulcerative Colitis
Many of our clients are pursuing groundbreaking therapies in disease areas with high unmet medical needs, giving our firm the chance to...
- Aug 5, 2021
Top 5 uncertainties we tackle when creating revenue forecast models
One of our most sought-after commercial strategy services is the creation of revenue forecasts. As such, we’ve spent numerous projects...
- May 26, 2021
Recent advances in antisense oligonucleotide therapy development
Our work at Headland covers a wide range of diseases and therapeutic areas, and we try to stay abreast of recent news and developments in...
- Dec 23, 2020
The mystery of risk-taking in biotech (US, Japan)
As we’ve expanded our US-Japan services, we are often asked about the differences between the US and Japanese biopharma industry. There...
- Aug 7, 2020
BIO 2020 Highlights
Last month we attended the first completely virtual BIO conference. We met with many innovative companies and are looking forward to...
- Aug 7, 2020
Initiative on Racial Justice and Equality
A note from our CEO, President, and Founder: My team and I are deeply troubled by the ongoing examples of violence, cruelty, and...
bottom of page